Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
2,5-Diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1) is a novel antitumor diaziridinyl benzoquinone derivative designed to be bioactivated by the two-electron reductase NAD(P)H:quinone oxidoreductase (NQO1) and is currently in clinical trials. NQO1 is expressed at high levels in many solid tumors. RH1 cytotoxicity has been shown previously to be NQO1-dependent. The purpose of this study was to investigate whether other reducing enzymes such as cytochrome b(5) reductase (b5R), cytochrome P450 reductase (P450R), dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2), and xanthine oxidase/xanthine dehydrogenase (XO/XDH) also contribute to the bioactivation and cytotoxicity of RH1 in human tumor cells. For these studies, we established a series of stable MDA468 breast cancer cell lines overexpressing various levels of NQO1, b5R, P450R, and NQO2 and compared RH1-induced growth inhibition [3-(4,5-dimethylthiazol-2,5-diphenyl)tetrazolium and sulforhodamine B analysis] and interstrand DNA cross-linking (comet analysis) in both parental MDA468 cells and transfected clones. RH1 toxicity correlated with NQO1 and NQO2 but not with either b5R or P450R activity levels in the respective series of transfected MDA468 cell clones. Enzymatic assays showed that RH1 was an in vitro substrate for xanthine oxidase. However, XO/XDH protein and activity could not be detected in a variety of human tumor cell lines. These studies suggest that NQO1 and NQO2 are the principal enzymatic determinants of RH1 bioactivation in MDA468 tumor cells and that b5R, P450R, and XDH/XO are unlikely to play major roles. Our studies also suggest that NQO2 may be particularly relevant as a bioactivation system for RH1 in NQO1-deficient tumors such as leukemias and lymphomas.
Yan
Chao
C
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, Denver, Colorado 80045, USA.
Kepa
Jadwiga K
JK
Siegel
David
D
Stratford
Ian J
IJ
Ross
David
D
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D001388:Aziridines / Q000378:metabolism / Q000494:pharmacology*; D016227:Benzoquinones / Q000378:metabolism / Q000494:pharmacology*; D045744:Cell Line, Tumor; D015786:Cytochromes b5 / Q000378:metabolism; D006801:Humans; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism*; D009251:NADPH-Ferrihemoprotein Reductase / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism*; D011808:Quinone Reductases / Q000378:metabolism; D014968:Xanthine Dehydrogenase / Q000378:metabolism; D014969:Xanthine Oxidase / Q000378:metabolism
C117776:2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone; D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; D015786:Cytochromes b5; D010088:Oxidoreductases; D014968:Xanthine Dehydrogenase; D014969:Xanthine Oxidase; D009251:NADPH-Ferrihemoprotein Reductase; D016660:NAD(P)H Dehydrogenase (Quinone); C447479:NQO1 protein, human; C419642:NRH - quinone oxidoreductase2; D011808:Quinone Reductases
J Biol Chem. 1978 Apr 25;253(8):2694-704
632295
Cancer Commun. 1991 Jul;3(7):199-206
1714284
J Biol Chem. 1984 Jan 25;259(2):959-66
6319393
Arch Biochem Biophys. 1997 Nov 15;347(2):221-8
9367528
Cancer Res. 1992 Sep 1;52(17):4752-7
1324793
Free Radic Biol Med. 1992 Dec;13(6):599-608
1334033
Nat Biotechnol. 2007 Sep;25(9):1035-44
17721511
Anticancer Res. 2003 Sep-Oct;23(5A):3979-83
14666706
Cancer Res. 2000 Aug 1;60(15):4179-86
10945627
Biochem Pharmacol. 2000 Apr 15;59(8):993-6
10692564
J Biol Chem. 1969 Jul 25;244(14):3855-63
4308738
Biochem Pharmacol. 1992 Oct 20;44(8):1625-35
1301071
Biochem Pharmacol. 1992 Jul 7;44(1):25-31
1385952
Free Radic Res. 2006 Sep;40(9):974-8
17015278
Free Radic Biol Med. 1989;6(1):63-101
2492250
Methods Enzymol. 1978;52:102-8
672620
J Pharmacol Exp Ther. 2005 May;313(2):771-9
15665137
Clin Cancer Res. 2004 May 1;10(9):3147-55
15131056
J Med Chem. 1998 Nov 19;41(24):4755-66
9822546
Cancer Res. 1993 Oct 15;53(20):4907-12
8402680
Biochemistry. 2004 Sep 14;43(36):11417-26
15350128
Cancer Res. 1990 Dec 15;50(24):7789-92
2123741
Blood. 2007 Dec 1;110(12):4055-63
17720881
Cancer Chemother Pharmacol. 2007 Nov;60(6):851-61
17333193
Free Radic Biol Med. 1989;6(6):607-15
2753392
Anticancer Drugs. 2005 Apr;16(4):381-91
15746574
Biochem Pharmacol. 2001 Jun 15;61(12):1509-16
11377380
Biochem Pharmacol. 1991 Aug 8;42(5):1021-7
1651729
Cancer Chemother Pharmacol. 2007 Oct;60(5):713-23
17256129
Anticancer Drugs. 2004 Jan;15(1):71-7
15090746
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6606682
Biochem Pharmacol. 1998 Aug 15;56(4):405-14
9763215
Jpn J Cancer Res. 1998 Sep;89(9):910-5
9818026
Biochem Pharmacol. 2000 Apr 1;59(7):831-7
10718341
J Natl Cancer Inst. 1996 Mar 6;88(5):259-69
8614004
Environ Mol Mutagen. 2000;35(3):206-21
10737956
Clin Cancer Res. 1998 Dec;4(12):3083-8
9865924
Nat Protoc. 2006;1(3):1112-6
17406391
Mol Pharmacol. 2001 Feb;59(2):263-8
11160862
Br J Cancer. 2006 Nov 6;95(9):1229-33
17031400
Biochem Pharmacol. 1997 Apr 25;53(8):1115-21
9175716
J Biol Chem. 1951 Nov;193(1):265-75
14907713